In the latest quarter, 16 analysts provided ratings for UnitedHealth Group UNH, showcasing a mix of bullish and bearish perspectives.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 12 | 0 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 4 | 7 | 0 | 0 | 0 |
2M Ago | 0 | 3 | 0 | 0 | 0 |
3M Ago | 0 | 1 | 0 | 0 | 0 |
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $616.94, along with a high estimate of $675.00 and a low estimate of $591.00. A decline of 0.31% from the prior average price target is evident in the current average.
Exploring Analyst Ratings: An In-Depth Overview
In examining recent analyst actions, we gain insights into how financial experts perceive UnitedHealth Group. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Andrew Mok | Barclays | Lowers | Overweight | $603.00 | $604.00 |
Gary Taylor | TD Cowen | Raises | Buy | $609.00 | $601.00 |
Kevin Caliendo | UBS | Lowers | Buy | $650.00 | $680.00 |
Scott Fidel | Stephens & Co. | Lowers | Overweight | $605.00 | $632.00 |
Sarah James | Cantor Fitzgerald | Raises | Overweight | $644.00 | $591.00 |
David Macdonald | Truist Securities | Lowers | Buy | $625.00 | $640.00 |
Ben Hendrix | RBC Capital | Lowers | Outperform | $595.00 | $615.00 |
Matthew Gillmor | Keybanc | Lowers | Overweight | $650.00 | $675.00 |
Ricky Goldwasser | Morgan Stanley | Lowers | Overweight | $610.00 | $615.00 |
Kevin Fischbeck | B of A Securities | Lowers | Buy | $650.00 | $675.00 |
Matthew Gillmor | Keybanc | Announces | Overweight | $675.00 | - |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $591.00 | $591.00 |
Key Insights:
- Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to UnitedHealth Group. This information provides a snapshot of how analysts perceive the current state of the company.
- Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of UnitedHealth Group compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for UnitedHealth Group's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of UnitedHealth Group's market position. Stay informed and make well-informed decisions with our Ratings Table.
Stay up to date on UnitedHealth Group analyst ratings.
All You Need to Know About UnitedHealth Group
UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 50 million members globally, including 1 million outside the us as June 2024. As a leader in employer-sponsored, self-directed, and government-backed insurance plans, UnitedHealth has obtained massive scale in managed care. Along with its insurance assets, UnitedHealth's continued investments in its Optum franchises have created a healthcare services colossus that spans everything from medical and pharmaceutical benefits to providing outpatient care and analytics to both affiliated and third-party customers.
UnitedHealth Group: Financial Performance Dissected
Market Capitalization Highlights: Above the industry average, the company's market capitalization signifies a significant scale, indicating strong confidence and market prominence.
Revenue Growth: UnitedHealth Group displayed positive results in 3 months. As of 30 June, 2024, the company achieved a solid revenue growth rate of approximately 6.61%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: UnitedHealth Group's net margin excels beyond industry benchmarks, reaching 4.31%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.79%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): UnitedHealth Group's ROA stands out, surpassing industry averages. With an impressive ROA of 1.48%, the company demonstrates effective utilization of assets and strong financial performance.
Debt Management: With a high debt-to-equity ratio of 0.84, UnitedHealth Group faces challenges in effectively managing its debt levels, indicating potential financial strain.
How Are Analyst Ratings Determined?
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.